SUNNYVALE, Calif.--(BUSINESS WIRE)--Embolx, Inc., a medical device company, announced today that the Company has received a Federal Supply Schedule contract from the U.S. Department of Veterans Affairs (VA) to provide Embolx’s Sniper® balloon occlusion microcatheter, an innovative system for pressure-directed embolization therapy, to their VA hospitals across the country.
The Sniper balloon occlusion microcatheter alters blood flow‐dynamics by controlling pressure to increase therapeutic agent delivery into target areas for the treatment of cancerous tumors, benign prostatic hyperplasia (BPH), and uterine fibroids. This therapy allows interventional radiologist physicians to deliver drugs and embolic agents to targeted treatment areas while protecting surrounding healthy tissues.
“We are honored to partner with the U.S. Department of Veterans Affairs and the associated VA hospitals that support the needs of our veterans,” said Michael Allen, President and CEO of Embolx. “Now the men and women who serve our country will have access to Sniper, the most advanced transarterial delivery system for super-selective tumor therapy and minimally invasive treatment for BPH.”
The Veterans Health Administration is America’s largest integrated health care system, providing health care at 1,240 facilities, including 170 medical centers and 1,061 outpatient sites, serving 9 million enrolled Veterans each year.
Embolx is an emerging commercial-stage medical device company in Silicon Valley developing microcatheters for arterial embolization procedures. Embolx is committed to dramatically improving the treatment of a variety of conditions including cancerous tumors, benign prostatic hyperplasia and uterine fibroids. The Sniper® balloon occlusion microcatheter sets a new standard for precise embolic delivery and superior target filling by controlling pressure to direct blood flow while protecting non-target surrounding tissues. For more information, please visit www.Embolx.com.